The National Sickle Cell Anaemia Elimination Mission crosses its 7-crore target, uncovering 2.4 lakh patients and nearly 20 lakh carriers across 278 districts — the world’s largest genetic screening campaign for a single inherited disease
India has crossed a landmark that no country has previously attempted at this scale: 7 crore — 70 million — individuals screened for sickle cell disease and trait under a single national mission in less than three years. The National Sickle Cell Anaemia Elimination Mission (NSCAEM), launched on 1 July 2023 by Prime Minister Narendra Modi at Shahdol, Madhya Pradesh, has now effectively achieved its core quantitative target for the 2025–26 period, generating in the process what is almost certainly the world’s largest population-level genetic dataset on a single inherited haemoglobin disorder.
Parliamentary figures as of 3 February 2026 placed confirmed screenings at 6.83 crore, with 2,37,981 individuals diagnosed with sickle cell disease (SCD) and 19,32,500 identified as carriers of the sickle gene. The subsequent crossing of the 7-crore threshold brings cumulative detected cases to approximately 2.4–2.5 lakh and carriers to roughly 19–20 lakh — numbers that, for the first time, give India a reliable, district-level picture of a disease burden that had remained largely unmapped for decades.
What Sickle Cell Disease Actually Does — and Why India Carries Half the World’s Burden
Sickle cell disease is an inherited mutation in the beta-globin gene that causes red blood cells to assume a rigid, crescent shape instead of the flexible disc that allows normal circulation. The consequences are severe and lifelong: chronic haemolytic anaemia that leaves the body perpetually oxygen-starved; vaso-occlusive crises in which sickled cells block small blood vessels, causing intense pain and progressive organ damage; heightened vulnerability to bacterial infections; and complications affecting the lungs, heart, kidneys, eyes, brain and bones. In remote tribal settings with limited access to specialist care, these consequences translate directly into premature death, school drop-out, loss of agricultural productivity and intergenerational poverty.
India accounts for roughly half of global SCD incidence — a consequence of the sickle gene’s deep entrenchment in many tribal populations across central, western and southern India, where the mutation historically conferred partial protection against malaria. Heterozygote (carrier) prevalence in some communities — the Garasiya and Bhil of Rajasthan, tribal clusters in Madhya Pradesh and Chhattisgarh — reaches 10–40%, one of the highest rates anywhere in the world. Yet until NSCAEM, most of these communities had never been systematically screened, leaving patients to be diagnosed only when a crisis presented at a district hospital.
Architecture of the Mission
Announced in the Union Budget 2023 and formally launched six months later, NSCAEM is implemented across 278 districts in 17 high-focus states — Gujarat, Maharashtra, Rajasthan, Madhya Pradesh, Jharkhand, Chhattisgarh, West Bengal, Odisha, Tamil Nadu, Telangana, Andhra Pradesh, Karnataka, Assam, Uttar Pradesh, Kerala, Bihar and Uttarakhand — under the joint stewardship of the Ministry of Health and Family Welfare (MoHFW) and the Ministry of Tribal Affairs (MoTA), anchored within the National Health Mission (NHM).
Screening reaches the population through a cascade of health facilities — from district hospitals and community health centres down to Ayushman Arogya Mandirs and outreach camps — and focuses on the 0–40 age group, the cohort of reproductive and early-developmental significance. Every screened individual receives a colour-coded sickle-cell genetic status card: a simple, portable document designed to accompany them through pre-marital and pre-conception counselling and to communicate genetic risk to family members. As of mid-2025, 2.6 crore such cards had been distributed.
For the first time, India has a reliable, district-level map of a disease that had remained largely invisible in its most vulnerable communities for decades.
A national SCD portal (sickle.nhm.gov.in) captures real-time data on screening outcomes, confirmatory testing, disease and trait status, and follow-up care — creating a live registry that can track programme coverage, flag geographic gaps and monitor clinical outcomes at scale. This digital infrastructure is a significant public-health innovation in its own right, enabling adaptive governance of a mission spanning 278 districts and 17 states.
From Detection to Care
NSCAEM is emphatically not a screening-only programme. Hydroxyurea, the disease-modifying oral therapy that reduces the frequency of painful crises and hospital admissions by inducing fetal haemoglobin production, has been added to the Essential Drugs List at sub-health centres, primary health centres, community health centres and district hospitals under NHM financial support — removing cost as a barrier to treatment for the first time in many tribal areas.
At the specialised end, the Mission envisages Integrated Centres for Haemoglobinopathies and Haemophilia at district hospitals and dedicated Centres of Excellence funded by MoTA, supported by training of master trainers through ICMR’s National Institute of Research in Tribal Health (NIRTH) in Jabalpur. Mega medical camps — such as the 2025 Sundargarh camp in Odisha, conducted with AIIMS Delhi participation — demonstrate how SCD services are being embedded in broader tribal-health outreach rather than siloed as a separate vertical.
Genetic counselling occupies a central place in programme design, recognising that detection without prevention counselling merely documents suffering rather than reducing it. When both parents carry the sickle trait, each pregnancy carries a 25% probability of producing a child with SCD. Informing couples of this risk — and supporting them in understanding their reproductive options — is the mechanism through which screening translates into the elimination of new cases over the long term.
Where the Disease Concentrates
State-wise parliamentary data from early 2024 point to Odisha (over 49,000 confirmed cases in tribal areas), Chhattisgarh (over 18,000), Maharashtra (around 15,000) and Madhya Pradesh (over 11,000) as the highest-burden states. The detection yield across the screened cohort — approximately 0.35–0.4% for confirmed SCD and 2.5–3% for carriers — broadly validates pre-mission estimates from tribal screening studies, while the granularity of the district-level data now allows targeted deployment of clinical and counselling resources that was previously impossible.
Consent, Stigma &Community Trust
Large-scale genetic screening of marginalised communities raises ethical questions that cannot be subordinated to programmatic targets. Informed consent in populations with low literacy, in languages and idioms that convey genetic probability meaningfully, is technically and culturally demanding. Carrier status can attract social stigma, affect marriage prospects and, without adequate safeguards, lead to discrimination that compounds the vulnerabilities these communities already face.
NSCAEM’s reliance on local health workers, community leaders, culturally tailored IEC materials and participatory outreach reflects an awareness of these tensions. But experts emphasise that monitoring for stigma and coercive practices, and the availability of legal and psychosocial support where needed, must keep pace with the mission’s expanding footprint as it transitions from initial screening to long-term follow-up and counselling at scale.
The Road to 2047
Reaching 7 crore screenings fulfils the first and most visible pillar of NSCAEM. The harder, longer work lies ahead. Continuous screening of new birth cohorts and migrants into high-burden areas; robust clinical follow-up for the 2.4 lakh diagnosed patients; high-quality, non-coercive counselling for 20 lakh carriers and their families; and measurable change in marriage and reproductive decisions at the community level — these are the variables that will determine whether 2047 is a genuine elimination milestone or merely a numerical one.
The Council of Scientific and Industrial Research (CSIR) has supported gene-editing research for SCD at CSIR-IGIB, exploring curative strategies that may eventually complement prevention. Should such therapies reach affordable deployment at scale within India’s public health system — a prospect that global advances in base editing and CRISPR-based approaches are beginning to make conceivable — they would represent a third pillar alongside screening-prevention and chronic care management.
For now, the 7-crore milestone is a genuine achievement in both public health administration and health equity. Seventy million people — most of them from communities that have historically been invisible to the formal health system — have been told, for the first time, something precise and actionable about their genetic health. That knowledge, if accompanied by the counselling, care and community trust that the Mission promises, is the foundation on which elimination becomes possible.
– Dr. Srinayani Kavuri
